NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$127.3m

Last Updated

2021/05/13 08:20 UTC

Data Sources

Company Financials

Executive Summary

Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Little Green Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LGP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: LGP's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-4.4%

LGP

-5.5%

AU Pharmaceuticals

-0.7%

AU Market


1 Year Return

75.7%

LGP

-4.2%

AU Pharmaceuticals

35.4%

AU Market

Return vs Industry: LGP exceeded the Australian Pharmaceuticals industry which returned -4.2% over the past year.

Return vs Market: LGP exceeded the Australian Market which returned 35.4% over the past year.


Shareholder returns

LGPIndustryMarket
7 Day-4.4%-5.5%-0.7%
30 Day-17.7%-11.1%0.8%
90 Day-18.8%-16.5%2.5%
1 Year75.7%75.7%-4.1%-4.2%39.6%35.4%
3 Yearn/a-44.0%-44.5%30.2%14.8%
5 Yearn/a-34.5%-37.8%61.7%31.7%

Long-Term Price Volatility Vs. Market

How volatile is Little Green Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Little Green Pharma undervalued compared to its fair value and its price relative to the market?

5.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LGP is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: LGP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LGP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LGP is overvalued based on its PB Ratio (5.8x) compared to the AU Pharmaceuticals industry average (3.1x).


Future Growth

How is Little Green Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

69.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Little Green Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Little Green Pharma performed over the past 5 years?

-28.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LGP is currently unprofitable.

Growing Profit Margin: LGP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LGP is unprofitable, and losses have increased over the past 5 years at a rate of 28.8% per year.

Accelerating Growth: Unable to compare LGP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LGP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).


Return on Equity

High ROE: LGP has a negative Return on Equity (-22.24%), as it is currently unprofitable.


Financial Health

How is Little Green Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: LGP's short term assets (A$8.0M) exceed its short term liabilities (A$2.2M).

Long Term Liabilities: LGP's short term assets (A$8.0M) exceed its long term liabilities (A$1.4M).


Debt to Equity History and Analysis

Debt Level: LGP is debt free.

Reducing Debt: LGP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LGP has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: LGP is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Little Green Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LGP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LGP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LGP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LGP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LGP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average board tenure


CEO

Fleta Solomon

no data

Tenure

AU$621,846

Compensation

Ms. Fleta Jennifer Solomon serves as Managing Director at Little Green Pharma Ltd. She serves as Director of Little Green Pharma Ltd since May 29, 2017. She joins Little Green Pharma Ltd in February 2017. ...


CEO Compensation Analysis

Compensation vs Market: Fleta's total compensation ($USD481.34K) is above average for companies of similar size in the Australian market ($USD289.57K).

Compensation vs Earnings: Fleta's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: LGP's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.3%.


Top Shareholders

Company Information

Little Green Pharma Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Little Green Pharma Ltd
  • Ticker: LGP
  • Exchange: ASX
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$127.347m
  • Shares outstanding: 187.27m
  • Website: https://www.littlegreenpharma.com

Location

  • Little Green Pharma Ltd
  • Level 2
  • Suite 2
  • West Perth
  • Western Australia
  • 6005
  • Australia

Listings


Biography

Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. It offers a range ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 08:20
End of Day Share Price2021/05/13 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.